Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:41 am EDT
79.10 SEK   +0.89%
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xbrane Biopharma AB(OM:XBRANE) dropped from OMX Nordic Small Cap Index

01/04/2022 | 12:00am EDT
share with twitter
share with LinkedIn
share with facebook

"Xbrane Biopharma AB (publ) has been removed from OMX Nordic Small Cap Index


© S&P Capital IQ 2022
All news about XBRANE BIOPHARMA AB (PUBL)
05/05Announcement from Xbrane Biopharma's annual general meeting
AQ
05/05TRANSCRIPT : Xbrane Biopharma AB, Q1 2022 Earnings Call, May 05, 2022
CI
05/05Xbrane Biopharma releases interim report for January – March 2022
AQ
05/05Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/02Invitation to presentation of Xbrane Biopharma's interim report January – March 2..
AQ
04/05Correction regarding notice of annual general meeting in Xbrane Biopharma
AQ
04/04Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/31Xbrane Biopharma releases annual report 2021
AQ
03/09Xbrane Biopharma - Xciting and Increasingly Compelling Case
AQ
02/24TRANSCRIPT : Xbrane Biopharma AB, Q4 2021 Earnings Call, Feb 24, 2022
CI
More news
Financials
Sales 2021 18,7 M 1,88 M 1,88 M
Net income 2021 -225 M -22,6 M -22,6 M
Net cash 2021 445 M 44,7 M 44,7 M
P/E ratio 2021 -8,05x
Yield 2021 -
Capitalization 1 981 M 199 M 199 M
EV / Sales 2021 82,0x
EV / Sales 2022 5,75x
Nbr of Employees 64
Free-Float 66,3%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 79,10 SEK
Average target price 235,00 SEK
Spread / Average Target 197%
EPS Revisions
Managers and Directors
Martin Åmark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikström Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)-24.52%199
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567